无创肝纤维化指标对肝硬化患者高风险胃食管静脉曲张的预测价值

林小钰; 胡晓敏; 陈永鹏

doi:10.3969/j.issn.1001-5256.2020.08.013

无创肝纤维化指标对肝硬化患者高风险胃食管静脉曲张的预测价值

DOI: 10.3969/j.issn.1001-5256.2020.08.013

1. 南方医科大学南方医院感染内科
2. 南方医科大学深圳医院肝病中心

基金项目:

十三五国家科技重大项目(2017ZX10203202-003-004,2018ZX10302204-001-002)；深圳市医学三名工程项目(SZSM201911001)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1425
- HTML全文浏览量: 37
- PDF下载量: 206
- 被引次数: 0
出版历程
- 出版日期: 2020-08-20

Value of noninvasive liver fibrosis markers in predicting high-risk gastroesophageal varices in patients with liver cirrhosis

Department of Infectious Diseases, Nanfang Hospital, Southern Medical University

Research funding:

摘要

摘要:
目的评估常规肝纤维化指标在肝硬化患者高风险胃食管静脉曲张（HRGOV）非创伤性诊断中的临床应用价值。方法选取2018年1月-12月于南方医科大学南方医院接受胃镜检查以及常规实验室检查的肝硬化患者165例，以胃镜检查为金标准，结合Child-Pugh评分诊断有无HRGOV。计量资料两组间比较采用独立样本t检验或Mann-Whitney U检验；计数资料两组间比较采用χ2检验。计算并比较受试者工作特征曲线下面积（AUC），应用似然比确定诊断、排除界值。结果165例患者中83例（50.3%）发生HRGOV；HRGOV组与非HRGOV组比较，Alb（t=-5.118，P＜0.001）、血小板计数（Z=-5.409，P＜0.001）、男性比例（χ2=3.883，P=0.049）、PT（Z=-4.433，P＜0.001）、PTA（Z=-4.447，P＜0.001）、INR（Z=-4.426，P＜0.001）、WBC（Z=-2.371，P=0.018）、脾厚度（Z=-6.296，P＜0.001）、天门冬氨酸转氨酶-血小板比值（APRI）（Z=-3.409，P=0.001）、肝纤维化4因子（FIB-4）（Z=-4.494，P＜0.001）、γ-谷氨酰转肽酶-血小板比值（GPR）（Z=-2.377，P=0.017）、红细胞体积分布宽度-血小板比值（RPR）（Z=-5.345，P＜0.001）、简易肝纤维化检测（eLIFT）（t=3.170，P=0.002）、胃镜分级（χ2=131.714，P＜0.001）、Child-Pugh分级（χ2=30.663，P＜0.001）差异均有统计学意义。超声脾厚度、血小板计数、RPR、FIB-4、APRI、eLIFT、GPR诊断HRGOV的AUC依次为0.785、0.747、0.744、0.703、0.652、0.622、0.606，AUC＞0.7的模型之间比较差异均无统计学意义（P值均＞0.05）。应用脾厚度＜29.5 mm排除诊断，脾厚度≥53.0 mm确定诊断，51例（30.9%）患者免于行胃镜检查，准确度为94.1%；应用RPR＜0.067排除诊断、RPR≥0.480确定诊断，19例（11.5%）患者免于胃镜检查，准确度为89.5%；脾厚度序贯联合RPR确定63例（38.2%）患者有无HRGOV，准确度为92.1%。结论脾厚度、RPR、血小板计数、FIB-4诊断HRGOV具有中等效能，诊断效能依次减弱；常规指标超声脾厚度序贯联合RPR可应用于临床筛查肝硬化HRGOV而免除部分患者胃镜检查。
- 肝硬化 /
- 食管和胃静脉曲张 /
- 诊断
Abstract:
ObjectiveTo investigate the clinical value of routine liver fibrosis markers in the noninvasive diagnosis of high-risk gastroesophageal varices (HRGOV) in patients with liver cirrhosis. MethodsA total of 165 patients with liver cirrhosis who underwent gastroscopy and routine laboratory examinations in Nanfang Hospital, Southern Medical University, from January to December 2018 were enrolled, and the presence or absence of HRGOV was determined based on the gold standard of gastroscopy with reference to Child-Pugh score. The independent samples t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. The area under the receiver operating characteristic curve (AUC) was calculated and compared, and likelihood ratio was used to confirm diagnosis and exclude cut-off values. ResultsOf all 165 patients, 83 (50.3%) patients were diagnosed with HRGOV. There were significant differences between the HRGOV group and the non-HRGOV group in albumin (t=-5.118, P＜0.001), platelet count (Z=-5.409，P＜0.001), proportion of male patients (χ2=3.883, P=0.049), prothrombin time (Z=-4.433, P＜0.001), prothrombin time activity (Z=-4.447, P＜0.001), international normalized ratio (Z=-4.426, P＜0.001), white blood cell count (Z=-2.371, P=0.018), spleen thickness (Z=-6.296, P＜0.001), aspartate aminotransferase-to-platelet ratio index (APRI) (Z=-3.409, P=0.001), fibrosis index based on four factors (FIB-4) (Z=-4.494, P＜0.001), gamma-glutamyl transpeptidase-to-platelet ratio (GPR) (Z=-2.377, P=0.017), red blood cell distribution width-to-platelet ratio (RPR) (Z=-5.345, P＜0.001), Easy Liver Fibrosis Test (eLIFT)(t=3.170, P=0.002), gastroscopic grade (χ2=131.714, P＜0001), and Child-Pugh class (χ2=30.663, P＜0.001). Spleen thickness on ultrasound, platelet count, RPR, FIB-4, APRI, eLIFT, and GPR had an AUC of 0.785, 0.747, 0.744, 0.703, 0.652, 0.622, and 0.606, respectively, in the diagnosis of HRGOV, and there was no significant difference between the models with an AUC of ＞0.7 (P＞0.05). With spleen thickness ＜29.5 mm for exclusion and spleen thickness ≥53.0 mm for confirmed diagnosis, 51 patients (30.9%) had no need to undergo gastroscopy, with a diagnostic accuracy of 94.1%; with RPR ＜0.067 for exclusion and RPR ≥0.480 for confirmed diagnosis, 19 patients (115%) had no need to undergo gastroscopy, with a diagnostic accuracy of 89.5%. Spleen thickness followed by RPR was used to confirm the presence or absence of HRGOV in 63 patients (38.2%) and achieved a diagnostic accuracy of 92.1%. ConclusionSpleen thickness, RPR, platelet count, and FIB-4 had moderate efficiency in the diagnosis of HRGOV, among which spleen thickness has the highest diagnostic efficiency, followed by RPR, platelet count, and FIB-4. Spleen thickness followed by RPR can be used for the screening for HRGOV in liver cirrhosis patients, helping some patients avoid gastroscopy.
- liver cirrhosis /
- esophageal and gastric varices /
- diagnosis

HTML全文

参考文献(21)

[1] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Endoscopy,Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol,2016,32(2):203-219.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．临床肝胆病杂志，2016,32(2):203-219.

[2] TSOCHATZIS EA,BOSCH J,BURROUGHS AK. Liver cirrhosis[J]. Lancet,2014,383(9930):1749-1761.

[3] GARCIA-TSAO G,ABRALDES JG,BERZIGOTTI A,et al. Portal hypertensive bleeding in cirrhosis:Risk stratification,diagnosis,and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology,2017,65(1):310-335.

[4] CHEN YP,HU XM,LIANG XE,et al. Stepwise application of fibrosis index based on four factors,red cell distribution width-platelet ratio,and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection[J]. J Gastroenterol Hepatol,2018,33(1):256-263.

[5] LEMOINE M,SHIMAKAWA Y,NAYAGAM S,et al. The gamma-glutamyl transpeptidase to platelet ratio(GPR)predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut,2016,65(8):1369-1376.

[6] BOURSIER J,de LEDINGHEN V,LEROY V,et al. A stepwise algorithm using an at-a-glance first-line test for the noninvasive diagnosis of advanced liver fibrosis and cirrhosis[J].J Hepatol,2017,66(6):1158-1165.

[7] CHEN YP,HUANG LW,LIN XY,et al. Alanine aminotransferase influencing performances of routine available tests detecting hepatitis B-related cirrhosis[J]. J Viral Hepat,2020.[Online ahead of print]

[8] WANG B,NIU JQ. Association of platelet count,fibrosis-4,and aspartate aminotransferase-to-platelet ratio index with the development and severity of esophageal varices in patients with liver cirrhosis[J]. J Clin Hepatol,2018,34(1):84-88.(in Chinese)王报，牛俊奇．PLT计数、FIB-4、APRI与肝硬化食管静脉曲张发生及严重程度的相关性分析[J]．临床肝胆病杂志，2018,34(1):84-88.

[9] THOMOPOULOS KC,LABROPOULOU-KARATZA C,MIMIDIS KP,et al. Non-invasive predictors of the presence of large oesophageal varices in patients with cirrhosis[J]. Dig Liver Dis,2003,35(7):473-478.

[10] KIM HY,SO YH,KIM W,et al. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices[J]. J Hepatol,2019,70(3):412-422.

[11] DAI L,DING HJ,LI LF,et al. Prediction of esophageal varices in hepatitis B-associated liver cirrhosis by parameters of liver and spleen ultrasonography[J]. Guangdong Med J,2008,29(6):951-953.(in Chinese)戴琳，丁慧俊，李林芳，等．肝脾超声波指标预测乙肝肝硬化食管静脉曲张[J]．广东医学，2008,29(6):951-953.

[12] Committee of Esophageal Varicosity,Society of Digestive Endoscopy of Chinese Medical Association. Tentative guidelines for endoscopic diagnosis and treatment of varicosity and variceal bleeding in digestive tract(2009)[J]. Chin J Dig Endosc,2010,27(1):1-4.(in Chinese)中华医学会消化内镜学分会食管胃静脉曲张学组．消化道静脉曲张及出血的内镜诊断和治疗规范试行方案(2009年)[J]．中华消化内镜杂志，2010,27(1):1-4.

[13] JAESCHKE R,GUYATT GH,SACKETT DL,et al. Users’guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group[J]. JAMA,1994,271(9):703-707.

[14] SEBASTIANI G,TEMPESTA D,FATTOVICH G,et al. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers:Results of a multicenter,largescale study[J]. J Hepatol,2010,53(4):630-638.

[15] HUANG R,YANG C,WU K,et al. Red cell distribution width as a potential index to assess the severity of hepatitis B virus-related liver diseases[J]. Hepatol Res,2014,44(14):e464-e470.

[16] DUAN ZH,ZHOU SY,LI ZK,et al. Value of platelet count-to-gallbladder wall thickness ratio score in predicting esophageal varices in patients with liver cirrhosis[J]. J Clin Hepatol,2019,35(12):2716-2720.(in Chinese)段志辉，周胜云，李增魁，等．血小板计数/胆囊壁厚度对肝硬化食管静脉曲张的预测价值[J]．临床肝胆病杂志，2019,35(12):2716-2720.

[17] QAMAR AA,GRACE ND,GROSZMANN RJ,et al. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis[J]. Hepatology,2008,47(1):153-159.

[18] CHEN YP,ZHANG Q,DAI L,et al. Is transient elastography valuable for high-risk esophageal varices prediction in patients with hepatitis-B-related cirrhosis?[J]. J Gastroenterol Hepatol,2012,27(3):533-539.

[19] JANGOUK P,TURCO L,de OLIVEIRA A,et al. Validating,deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis[J]. Liver Int,2017,37(8):1177-1183.

[20] BAE J,SINN DH,KANG W,et al. Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy[J]. Liver Int,2018,38(8):1442-1448.

[21] de FRANCHIS R,Baveno VI Faculty. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752.

施引文献

资源附件(0)

访问统计